Plcoskin

Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare. They have developed a scaffold that removes the need for cadaver-sourced material used in breast reconstruction surgery, making procedures safer and cheaper. Plcoskin’s scaffolds are made with synthetic PCL, a biodegradable material that is commonly used to create surgical sutures. Unlike competitors' products that remain in the body for a lifetime, Plcoskin’s PCL scaffolds are absorbed and replaced with the recipient’s own natural tissues, minimizing the possibility of long-term side effects. As they do not contain any dangerous chemicals, they are also 50% safer than cadaver-sourced scaffolds. Costs for reconstructive breast surgery are brought down by 40% to only $3 thousand per breast. Furthermore, much less handling time is required, reducing average surgery durations from an hour and a half to only 30 minutes. The mesh design of the scaffolds mitigates the need for an additional follow-up reconstructive surgery, something that is common when using cadaver-sourced scaffolds. In addition to their medical devices, Plcoskin has also developed Youlief, a cosmeceutical product & therapeutic device pipeline that helps fund R&D for their medical devices. Available in the US, Europe, Taiwan, Singapore and Japan, this diversification strategy supports the company’s financial health and stability. Founded in 2017 in South Korea, Plcoskin secured a Series B investment on 31 August 2023. Key investors in this round include SJ Investment Partners, WE Ventures, Tony Investment, HG Initiative, Stick Ventures, and Helio Investment. These investments position Plcoskin to continue its innovation and expansion within the Biopharma, Biotechnology, and Health Care industries.